Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: A case report

Journal of Neuro-Oncology

Volumn 84, Issue 1, 2007, Pages 103-105

  Altintas, Abdullah ^a   Cil, Timucin ^a   Kilinc, Ilhan ^a   Kaplan, Muhammet Ali ^a   Ayyildiz, Orhan ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Blasticphase; Chronic myeloid leukemia; Imatinibmesylate; Meningeal leukemia

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DEXAMETHASONE; DRUG METABOLITE; HYDROXYUREA; IMATINIB; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG ACTIVITY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; FATIGUE; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; NIGHT SWEAT;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; DEXAMETHASONE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SARCOMA, GRANULOCYTIC; TREATMENT OUTCOME;

EID: 34547107099     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9352-0     Document Type: Article

References (13)

1. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330-1340
2. Deininger MW, Goldman JM, Melo JW (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356
3. Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients. Am J Med 83:445-454
4. Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C (1990) A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukemia. Br J Haematol 76:27-32
5. Nadal E, Olavarria E (2004) Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukemia and other malignancies. J Clin Pract 58:511-516
6. Saikia TK, Dhabhar B, Iyer RS et al (1993) High incidence of meningeal leukemia in lymphoid blast crisis of chronic myeloid leukemia. Am J Hematol 43:10-13
7. Naito K, Mori T, Miyazaki K, Tsukada Y, Ikeda Y, Okamato S (2003) Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). Intern Med 42:740-742
8. Rytting M, Wierda WG (2004) Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 45:1623-1626
9. Pfeifer H, Wassmann B, Hofmann WK et al (2003) Risk and prognosis of central nervous system leukemia with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 9:4674-4681
10. Talpaz M, Silver RT, Druker BJ et al (2002) Imatinib induces durable hematologic andcytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Result of phase 2 study. Blood 99:1928-1937
11. Bornhauser M, Jenke A, Freiberg-Richter J et al (2004) CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 83:401-402
12. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist W (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092
13. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto SI (2002) Imatinib mesylate has a limited activity against the central nervous system involvement of Philadelphia-chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106-108 106-108